{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:41:54Z","timestamp":1788345714410,"version":"build-2803163510"},"reference-count":159,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Liqi","award":["Natural Science Foundation of Shanghai (19ZR145850"],"award-info":[{"award-number":["Natural Science Foundation of Shanghai (19ZR145850"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Gastric cancer (GC) is one of the most common gastrointestinal tract cancers worldwide, which has high incidence and mortality rates and poor prognosis. Although multidisciplinary comprehensive therapies consisting of surgery, chemotherapy, radiotherapy, and targeted therapy have made great progress in GC treatment, a satisfactory curative effect still cannot be achieved in many circumstances, and the 5-year survival of patients with GC remains to be very low. In China, about 75% of patients with GC are diagnosed in the advanced stage and thus miss the opportunity of surgical resection. Although the conventional treatment of GC has improved the survival time of advanced patients to a certain extent, the clinical efficacy has encountered a bottleneck and cannot bring higher survival benefits to patients. With the development of immunologic and molecular biologic technologies, immunotherapy has gradually become a new essential treatment for GC, which has attracted extensive attention in the field of oncology. The US Food and Drug Administration (USFDA) and China Food and Drug Administration (CFDA) have approved a variety of immune-related drugs for the treatment of GC, and all of which have achieved good efficacy. In this review, we summarize the recent development in nonspecific enhancer therapy, adoptive immunocell therapy, tumor vaccine therapy, oncolytic virus therapy, and immune checkpoint inhibitor therapy, and their roles in the treatment of GC.<\/jats:p>","DOI":"10.1177\/15330338221150555","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T01:58:23Z","timestamp":1681264703000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Research Progress of Immunotherapy for Gastric Cancer"],"prefix":"10.1177","volume":"22","author":[{"given":"Zhipeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Shuguang Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-3183","authenticated-orcid":false,"given":"Ningning","family":"Liu","sequence":"additional","affiliation":[{"name":"Shuguang Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-7283","authenticated-orcid":false,"given":"Mingyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Shuguang Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S206189"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2016.01942"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i7.1657"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1526084"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0221"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0581"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-01034-7"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6212"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040805"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy540"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3559"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06958-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419890020"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.8"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0903-1"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.4_suppl.tps188"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0508-1"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00892"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0011"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.007"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30326-0"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30169-8"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30458-9"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102985"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30271-0"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2019.10.08"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.233.dmkt"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1100789"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029304"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4"},{"issue":"8","key":"e_1_3_3_55_2","first-page":"1150","article-title":"Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial","volume":"8","author":"Stein A","year":"2022","unstructured":"Stein A, Paschold L, Tintelnot J, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial. JAMA Oncol. 2022;8(8):1150-1158.","journal-title":"JAMA Oncol"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0025"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"e_1_3_3_58_2","first-page":"1767","article-title":"Tremelimumab: research and clinical development","volume":"9","author":"Comin-Anduix B","year":"2016","unstructured":"Comin-Anduix B, Escuin-Ordinas H, Ibarrondo FJ. Tremelimumab: research and clinical development. Onco Targets Ther. 2016;9:1767-1776.","journal-title":"Onco Targets Ther"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2870"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112839"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz197"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4691"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-7802"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07251-z"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.741865"},{"issue":"3","key":"e_1_3_3_67_2","first-page":"493","article-title":"Clinical efficacy and safety of nab-paclitaxel plus ramucirumab therapy in patients with unresectable advanced or recurrent gastric cancer","volume":"47","author":"Murakami K","year":"2020","unstructured":"Murakami K, Takeno A, Masuzawa T, et al. Clinical efficacy and safety of nab-paclitaxel plus ramucirumab therapy in patients with unresectable advanced or recurrent gastric cancer. Gan To Kagaku Ryoho. 2020;47(3):493-495.","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx213"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028472"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1999.1511"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106296"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9239-x"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eacbc4"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2017.12.003"},{"issue":"28","key":"e_1_3_3_77_2","first-page":"2662","article-title":"A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa lentinan research group","volume":"46","author":"Nakano H","year":"1999","unstructured":"Nakano H, Namatame K, Nemoto H, et al. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa lentinan research group. Hepatogastroenterology. 1999;46(28):2662-2668.","journal-title":"Hepatogastroenterology"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00233-4"},{"issue":"3","key":"e_1_3_3_79_2","first-page":"161e9","article-title":"Effect of immunotherapy with lentinan on patients\u2019 survival and immunological parameters in patients with advanced gastric cancer: results of a multi-center randomized controlled study","author":"Ochiai T","year":"1992","unstructured":"Ochiai T, Isono K, Suzuki T, et al. Effect of immunotherapy with lentinan on patients\u2019 survival and immunological parameters in patients with advanced gastric cancer: results of a multi-center randomized controlled study. Int J Immunother. 1992;VIII(3):161e9.","journal-title":"Int J Immunother"},{"issue":"10","key":"e_1_3_3_80_2","first-page":"1264","article-title":"Evaluation of immunity in elderly patients with unresectable gastric cancer receiving S-1\/lentinan combination chemotherapy","volume":"41","author":"Fukuchi M","year":"2014","unstructured":"Fukuchi M, Mochiki E, Ishiguro T, et al. Evaluation of immunity in elderly patients with unresectable gastric cancer receiving S-1\/lentinan combination chemotherapy. Gan To Kagaku Ryoho. 2014;41(10):1264-1266.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"6","key":"e_1_3_3_81_2","first-page":"4707","article-title":"Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1\/Th2 balance in patients with digestive cancers","volume":"20","author":"Yoshino S","year":"2000","unstructured":"Yoshino S, Tabata T, Hazama S, et al. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1\/Th2 balance in patients with digestive cancers. Anticancer Res. 2000;20(6C):4707-4711.","journal-title":"Anticancer Res"},{"issue":"9","key":"e_1_3_3_82_2","first-page":"1289","article-title":"Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer","volume":"30","author":"Nimura H","year":"2003","unstructured":"Nimura H, Mitsumori N, Tsukagoshi S, et al. Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer. Gan To Kagaku Ryoho. 2003;30(9):1289-1296.","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v2.i10.339"},{"issue":"7","key":"e_1_3_3_84_2","first-page":"2739","article-title":"Individual patient based meta-analysis of lentinan for unresectable\/recurrent gastric cancer","volume":"29","author":"Oba K","year":"2009","unstructured":"Oba K, Kobayashi M, Matsui T, et al. Individual patient based meta-analysis of lentinan for unresectable\/recurrent gastric cancer. Anticancer Res. 2009;29(7):2739-2745.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0277-9"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-12-2"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0489-9"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(02)00124-X"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-004-0299-y"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2064"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00195"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13027"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4325874"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"},{"key":"e_1_3_3_98_2","first-page":"2183510","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals recurrent neoantigens as potential therapeutic targets","volume":"2019","author":"Chen C","year":"2019","unstructured":"Chen C, Zhou Q, Wu R, et al. A comprehensive survey of genomic alterations in gastric cancer reveals recurrent neoantigens as potential therapeutic targets. Biomed Res Int. 2019;2019:2183510.","journal-title":"Biomed Res Int"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/690643"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0285"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.2174\/1872214807666140107152008"},{"issue":"11","key":"e_1_3_3_102_2","first-page":"3394","article-title":"Dendritic cells pulsed with HER-2\/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer","volume":"8","author":"Kono K","year":"2002","unstructured":"Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2\/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8(11):3394-3400.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"e_1_3_3_103_2","first-page":"1111","article-title":"Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas","volume":"20","author":"Tanaka F","year":"2008","unstructured":"Tanaka F, Haraguchi N, Isikawa K, et al. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep. 2008;20(5):1111-1116.","journal-title":"Oncol Rep"},{"issue":"8","key":"e_1_3_3_104_2","first-page":"2277","article-title":"Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas","volume":"7","author":"Sadanaga N","year":"2001","unstructured":"Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001;7(8):2277-2284.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0491-7"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1154-7"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31551"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00145-6"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29553"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13387"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.11.001"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2003.tb01522.x"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00498.x"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-013-0258-6"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2017.03.004"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2004.03.009"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21814"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3742"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4234-8"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.3955"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1573"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2242"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01843.x"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2010.04.007"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051914-021702"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0400-z"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0384-8"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1159\/000502845"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"e_1_3_3_135_2","first-page":"5473292","article-title":"Efficacy of DC-CIK immunotherapy combined with chemotherapy on locally advanced gastric cancer","volume":"2022","author":"Liu G","year":"2022","unstructured":"Liu G, Chen D, Zhao X, et al. Efficacy of DC-CIK immunotherapy combined with chemotherapy on locally advanced gastric cancer. J Oncol. 2022;2022:5473292.","journal-title":"J Oncol"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S162281"},{"issue":"2","key":"e_1_3_3_137_2","first-page":"173","article-title":"Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines","volume":"20","author":"Sun S","year":"2005","unstructured":"Sun S, Li XM, Li XD, et al. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm. 2005;20(2):173-180.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-010-1111-7"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1289-2"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-118"},{"issue":"3","key":"e_1_3_3_141_2","first-page":"2237","article-title":"Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells","volume":"26","author":"Jiang J","year":"2006","unstructured":"Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006;26(3B):2237-2242.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/897214"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S107745"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2360"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i48.6155"},{"issue":"4","key":"e_1_3_3_146_2","first-page":"303","article-title":"Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients","volume":"28","author":"Zhao H","year":"2013","unstructured":"Zhao H, Fan Y, Li H, et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm. 2013;28(4):303-309.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08267-7"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0632-8"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.06.017"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.04.017"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690499"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<978::AID-IJC12>3.0.CO;2-2"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0693-8"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2324"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0258"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0919-y"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338221150555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338221150555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338221150555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:12:12Z","timestamp":1777702332000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338221150555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":159,"alternative-id":["10.1177\/15330338221150555"],"URL":"https:\/\/doi.org\/10.1177\/15330338221150555","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338221150555\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338221150555\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338221150555\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338221150555\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338221150555\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338221150555\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"15330338221150555"}}